BUSINESS WIRE; Monday, June 15, 1998
"For the first time, thousands of people who are passionately interested in new aspects of AIDS research, but unable to travel to the Conference, will be able to participate in the meeting," said Dr. Bernard Hirschel, Chair of the 12th World AIDS Conference. "We hope that this unprecedented global sharing of knowledge will stimulate new thinking in the battle against HIV disease."
Speaking on behalf of the International Council of AIDS Service Organizations, a co-organizer of the 12th World AIDS Conference, Mr. Richard Burzynski said, "Community-based organizations (CBOs), providing care and support to millions of people living with HIV around the world, need to continue initiating more effective programs and policies which make a difference in people's lives. The provision of information on the WWW is an additional resource for many of these groups and the people they serve. I believe that the organizers of the 12th World AIDS Conference have made a major step forward in attempting to take conference messages directly to audiences. This is a pioneering project and one which I hope will be established as a benchmark for all other conference organizers."
The World AIDS Conference takes place once every two years and is the largest international HIV/AIDS forum for sharing new clinical, scientific and social data. More than 10,000 delegates are expected to attend this year's Geneva meeting including scientists, physicians and other healthcare professionals, people with HIV/AIDS, representatives of community groups and social workers. In contrast to other types of media coverage, the Webcast format provides direct access to Conference presentations.
All selected presentations will be available for review online within eight hours of their initial public viewing in Geneva. In addition, daily summaries of the entire Conference will be available for review and print. The Webcast service will be available at the internet address: webcast.aids98.org and will be operational for the duration of the Conference and until December 31, 1999.
The Webcast is made possible by the financial sponsorship of Gilead Sciences, Inc., an independent biopharmaceutical company located in Foster City, California, USA. "We are very pleased to be able to support this pioneering project," said John C. Martin, Ph.D., Gilead's President and CEO. "By providing timely worldwide access to the comprehensive information presented at the Conference, the Webcast will make a significant contribution to the knowledge base of all who are involved in the global fight against HIV."
Gilead Sciences is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. The Company discovers, develops and commercializes proprietary therapeutics for important viral diseases, including a currently marketed product for the treatment of CMV retinitis, a sight-threatening viral infection in patients with AIDS. In addition, the Company is developing products to treat diseases caused by HIV, hepatitis B virus and influenza virus. Gilead common stock is traded on the Nasdaq Stock Market under the symbol GILD.
The Webcast service provider is MediTech Media Ltd., a medical communications agency with offices in London, Atlanta, Munich and Singapore. MediTech Media Ltd. specializes in the provision of innovative technological solutions to communications requirements in the healthcare field.
Members of the press can find detailed information and graphics regarding the Webcast at the following location: webcast.aids98.org/presspack/.
For further information on how to access the Webcast or its features, please contact:
Laurie Hurley Tel:+1 650 573 4894 Fax: +1 650 573 4853 Freephone: 1-800-GILEAD-5 or Susan Hubbard Tel:+1 650 573 4715 Fax: +1 650 573 4853 Freephone: 1-800-GILEAD-5 Gilead Sciences 333 Lakeside Drive Foster City CA 94404 USA
or
Rachelle Galloway or Justin Drew MediTech Media Ltd. (USA) 2989 Piedmont Road Atlanta GA 30305 USA Tel: +1 404 233 6446 Fax: +1 404 233 2827
--30--ms/sf*
CONTACT: Gilead Sciences Laurie Hurley, 650/573-4894 Freephone: 1-800-GILEAD-5 http://www.gilead.com or Susan Hubbard, 650/573-4715 Freephone: 1-800-GILEAD-5 or MediTech Media Ltd. (USA) Rachelle Galloway or Justin Drew, 404/233-6446
980615
BW980605
Copyright © 1998 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1998. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1998. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .